Last reviewed · How we verify
Sichuan Jishengtang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Shugan Jieyu Capsules | Shugan Jieyu Capsules | phase 3 | Traditional Chinese medicine | Psychiatry | ||
| Wujia Yizhi granules | Wujia Yizhi granules | phase 3 |
Therapeutic area mix
- Psychiatry · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- China Academy of Chinese Medical Sciences · 1 shared drug class
- Dongzhimen Hospital, Beijing · 1 shared drug class
- Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 1 shared drug class
- Jiangsu Famous Medical Technology Co., Ltd. · 1 shared drug class
- Shanghai University of Traditional Chinese Medicine · 1 shared drug class
- Tasly Pharmaceutical Group Co., Ltd · 1 shared drug class
- The First Affiliated Hospital of Guangzhou Medical University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sichuan Jishengtang Pharmaceutical Co., Ltd.:
- Sichuan Jishengtang Pharmaceutical Co., Ltd. pipeline updates — RSS
- Sichuan Jishengtang Pharmaceutical Co., Ltd. pipeline updates — Atom
- Sichuan Jishengtang Pharmaceutical Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sichuan Jishengtang Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sichuan-jishengtang-pharmaceutical-co-ltd. Accessed 2026-05-17.